Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in mauritian cynomolgus macaques

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Berry, Neil ^a   Ham, Claire ^a   Mee, Edward T ^a   Rose, Nicola J ^a   Mattiuzzo, Giada ^a   Jenkins, Adrian ^a   Page, Mark ^a   Elsley, William ^a   Robinson, Mark ^a   Smith, Deborah ^a   Ferguson, Deborah ^a   Towers, Greg ^b   Almond, Neil ^a   Stebbings, Richard ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRIPARTITE MOTIF PROTEIN 5; VIRUS RNA; CARRIER PROTEIN; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; IMMUNITY; LENTIVIRUS INFECTION; LYMPHOID TISSUE; MACACA; MAURITIAN CYNOMOLGUS MACAQUE; MIXED INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; ALLELE; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; IN SITU HYBRIDIZATION; KINETICS; LYMPHOCYTE COUNT; MACACA FASCICULARIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MAURITIUS; PATHOGENICITY; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SPECIES DIFFERENCE; TREATMENT OUTCOME; VIROLOGY;

MACACA; SIMIAN IMMUNODEFICIENCY VIRUS;

ALLELES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CARRIER PROTEINS; DNA, VIRAL; HAPLOTYPES; IN SITU HYBRIDIZATION; KINETICS; LYMPHOCYTE COUNT; LYMPHOID TISSUE; MACACA FASCICULARIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MAURITIUS; POLYMORPHISM, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES SPECIFICITY; TREATMENT OUTCOME; VACCINATION; VACCINES, ATTENUATED;

EID: 80051538295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023092     Document Type: Article

References (68)

1. Barouch DH, Korber B, (2010) HIV-1 vaccine development after STEP Ann Rev Med. 61: 153-167.
2. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
3. McCutchan FE, (2006) Global epidemiology of HIV. J Med Virol 78: S7-S12.
4. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, et al. (2006) HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7: 19-23.
5. Abel K, Compton L, Rourke T, Montefiori D, Lu D, et al. (2003) Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol 77: 3099-3118.
6. Ahmed RK, Nilsson C, Wang Y, Lehner T, Biberfeld G, et al. (1999) Beta-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge. J Gen Virol 80: 1569-1574.
7. Almond N, Kent K, Cranage M, Rud E, Clarke B, et al. (1995) Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345: 1342-1344.
8. Berry N, Stebbings R, Ferguson D, Ham C, Alden J, et al. (2008) Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol 89: 2240-2251.
9. Connor RI, Montefiori DC, Binley JM, Moore JP, Bonhoeffer S, et al. (1998) Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 72: 7501-7509.
10. Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, et al. (1997) Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229: 143-154.
11. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC, (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938-1941.
12. Johnson RP, Glickman RL, Yang JQ, Kaur A, Dion JT, et al. (1997) Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 71: 7711-7718.
13. Johnson RP, Lifson JD, Czajak SC, Cole KS, Manson KH, et al. (1999) Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 73: 4952-4961.
14. Mansfield K, Lang SM, Gauduin MC, Sanford HB, Lifson JD, et al. (2008) Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol 82: 4135-4148.
15. Nilsson C, Makitalo B, Thorstensson R, Norley S, Binninger-Schinzel D, et al. (1998) Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12: 2261-2270.
16. Norley S, Beer B, Binninger-Schinzel D, Cosma C, Kurth R, (1996) Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 219: 195-205.
17. Pahar B, Lackner AA, Piatak M Jr, Lifson JD, Wang X, et al. (2009) Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge. Virology 387: 273-284.
18. Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, et al. (2008) Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 205: 2537-2550.
19. Schmitz JE, Johnson PR, McClure H, Manson KM, Wyand M, et al. (2005) Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239Δ3-vaccinated rhesus macaques. J Virol 79: 8131-8141.
20. Sharpe SA, Whatmore AM, Hall GA, Cranage MP, (1997) Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-revertant virus. J Gen Virol 78: 1923-1927.
21. Sharpe S, Cope A, Dowall S, Berry N, Ham C, et al. (2004) Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to superinfection despite declining cytotoxic T lymphocyte responses to an immunodominant epitope. J Gen Virol 85: 2591-2602.
22. Stahl-Hennig C, Dittmer U, Nisslein T, Petry H, Jurkiewicz E, et al. (1996) Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol 77: 2969-2981.
23. Stebbings R, Stott J, Almond N, Hull R, Lines J, et al. (1998) Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. AIDS Res Hum Retroviruses 14: 1187-1198.
24. Stebbings R, Berry N, Stott J, Hull R, Walker B, et al. (2004) Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology 330: 249-260.
25. Stebbings R, Berry N, Waldmann H, Bird P, Hale G, et al. (2005) CD8+ lymphocytes do not mediate early protection against superinfection by inoculation with a live attenuated simian immunodeficiency virus. J Virol 79: 12264-12272.
26. Titti F, Sernicola L, Geraci A, Panzini G, Di Fabio S, et al. (1997) Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol 78: 2529-2539.
27. Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, et al. (2001) Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. J Gen Virol 82: 1601-1612.
28. Whatmore AM, Cook N, Hall GA, Sharpe S, Rud EW, et al. (1995) Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 69: 5117-5123.
29. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, et al. (1999) Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 73: 8356-8363.
30. Yeh WW, Jaru-Ampornpan P, Nevidomskyte D, Asmal M, Rao SS, et al. (2009) Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol 83: 2686-2696.
31. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, et al. (1995) Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267: 1820-1825.
32. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, et al. (1999) Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5: 1-10.
33. Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, et al. (2003) Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17: 157-166.
34. Gundlach BR, Lewis MG, Sopper S, Schnell T, Sodroski J, et al. (2000) Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. J Virol 74: 3537-3542.
35. Rud EW, Cranage M, Yon J, Quirk J, Ogilvie L, et al. (1994) Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol 75: 529-543.
36. Almond N, Rose J, Sangster R, Silvera P, Stebbings R, et al. (1997) Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J Gen Virol 78: 1919-1922.
37. Krebs KC, Jin Z, Rudersdorf R, Hughes AL, O'Connor DH, (2005) Unusually high frequency MHC class I alleles in Mauritian origin cynomolgus macaques. J Immunol 175: 5230-5239.
38. O'Connor SL, Blasky AJ, Pendley CJ, Becker EA, Wiseman RW, et al. (2007) Comprehensive characterization of MHC class II haplotypes in Mauritian cynomolgus macaques. Immunogenetics 59: 449-462.
39. Wiseman RW, Wojcechowskyj JA, Greene JM, Blasky AJ, Gopon T, et al. (2007) Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from Mauritius. J Virol 81: 349-61.
40. O'Connor S, Lhost JL, Becker EA, Detmer AM, Johmson RC, et al. (2010) MHC heterozygote advantage in simian immunodeficiency virus-infected Mauritian cynomolgus macaques. Sci Trans Med 2: 22ra18.
41. Greene JM, Lhost JL, Burwitz BJ, Budde ML, Macnair CE, et al. (2010) Extralymphoid CD8+ T cells resident in tissues from simian immunodeficiency virus SIVmac239Δnef-vaccinated macaques suppress SIVmac239 replication ex vivo. J Virol 84 (7): 3362-3372.
42. Greene JM, Burwitz BJ, Blasky AJ, Mattila TL, Hong JJ, et al. (2008) Allogeneic lymphocytes persist and traffic in feral MHC-matched Mauritian cynomolgus macaques. PLoS ONE 3: e2384.
43. Florese RH, Wiseman RW, Venzon D, Karl JA, Demberg T, et al. (2008) Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. Vaccine 26: 3312-3321.
44. Mee ET, Berry N, Ham C, Sauermann U, Maggiorella MT, et al. (2009) Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques. Immunogenetics 61: 327-339.
45. Mee ET, Berry N, Ham C, Aubertin A, Lines J, et al. (2010) Mhc haplotype M3 is associated with early control of SHIVsbg infection in Mauritian cynomolgus macaques. Tissue Antigens 76: 223-229.
46. Newman RM, Hall L, Kirmaier A, Pozzi L-A, Pery E, et al. (2008) Evolution of a TRIM5-CypA Splice Isoform in Old World Monkeys. PLoS Pathog 4: e1000003.
47. Clarke S, Almond N, Berry N, (2003) Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles in vivo. Virology 306: 100-108.
48. Lim S-Y, Rogers T, Chan T, Whitney JB, Kim J, et al. (2010) TRIM5alpha modulates immunodeficiency virus control in rhesus monkeys. PLOS Path 6: e1000738.
49. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, et al. (2010) TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 24;8 (8). pii: e1000462.
50. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, et al. (2009) Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 83: 6508-6521.
51. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, et al. (1998) Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280: 427-431.
52. Veazey RS, Mansfield KG, Tham IC, Carville AC, Shvetz DE, et al. (2000) Dynamics of CCR5 expression by CD4+ T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 74: 11001-11007.
53. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749-759.
54. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, et al. (2005) Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434: 1148-1152.
55. Mattapillil JL, Douek D, Hill B, Nishimura Y, Martin M, et al. (2005) Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097.
56. Li B, Berry N, Ham C, Ferguson D, Smith D, et al. (2011) Vaccination with live attenuated simian immunodeficiency virus causes dynamic changes in intestinal CD4+CCR5+ T cells Retrovirology 8: 8.
57. Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, et al. (2003) Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J Virol 77: 6823-6835.
58. Kumar AZ, Liu D, Sheffer M, Smith DK, Singh S, et al. (2008) Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration, Virology. 371: 238-245.
59. Yankee TM, Sheffer D, Liu Z, Dhillon S, Jia F, et al. (2009) Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques. Virology 383: 103-111.
60. Das AT, Klaver B, Centlivre M, Harwig A, Ooms M, et al. (2008) Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution. Retrovirology 5: 44.
61. Wodarz D, (2008) Immunity and protection by live attenuated HIV/SIV vaccines. Virology 378: 299-305.
62. Huthoff H, Towers GJ, (2008) Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends Microbiol 16: 612-619.
63. Neil S, Bieniasz P, (2009) Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 29: 569-580.
64. Hirsch VM, Johnson PR, (1994) Pathogenic diversity of simian immunodeficiency viruses. Virus Res 32: 183-203.
65. Ham C, Srinivasan P, Thorstensson R, Vershoor E, Vagrouche Z, et al. (2010) An International multi-centre study to assess a panel of reference materials for SIV RNA quantification. J Clin Micro 48: 2582-2585.
66. Silvera P, Wade-Evans A, Rud E, Hull R, Silvera K, et al. (2001) Mechanisms of protection induced by live attenuated simian immunodeficiency virus: III. Viral interference and the role of CD8+ T-cells and beta-chemokines in the inhibition of virus infection of PBMCs in vitro. J Med Primatol 30: 1-13.
67. Canto-Nogues C, Jones S, Sangster R, Silvera P, Hull R, et al. (2001) In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo. J Gen Virol 82: 2225-2234.
68. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24 (8): 1596-1599.